Perkinelmer

NYSE:PKI   4:00PM EDT
84.10
+1.00 (+1.20%)
StockTwits Share  Twitter Share  Facebook Share

Search For a Symbol

Market Cap (Intraday)9.34B
Current PE37.02
Forward PE 20.87
2yr Forward PE 18.24
See more stats...
Estimates Current Quarter
Revenue$722.52 Million
Adjusted EPS$1.01
See more estimates...
10-Day MA$82.99
50-Day MA$83.29
200-Day MA$89.77
See more pivots...

PERKINELMER INC Stock, NYSE:PKI

940 WINTER STREET, WALTHAM, MA 02451
United States of America
Phone: 781 663 5776
Number of Employees: 8000

Description

PerkinElmer, Inc. provides products, services, and solutions to the diagnostics, research, environmental, industrial, food, and laboratory services markets worldwide. The company operates through two segments, Discovery and Analytical Solutions and Diagnostics. The Discovery and Analytical Solutions segment develops and provides analytical technologies, solutions, and services that enable its customers to understand the characterization and health of various aspects, including air, water, and soil. It also provides solutions to farmers and food producers; an analytical instrumentation for the industrial market, which includes the chemical, electronics, energy, food, lubricant, petrochemical, and polymer industries; and laboratory services. This segment's offers a suite of solutions, including reagents, liquid handling systems, and detection and imaging technologies that enable scientists to enhance life sciences research and drug discovery processes. Its research portfolio includes a range of systems consisting of imaging, detection, and extraction instrumentation for use on in vitro, ex vivo, and in vivo models, analysis hardware, and software; and a range of consumable products, including drug discovery and research reagents. The Diagnostics segment provides early detection for genetic disorders from pregnancy to early childhood, as well as flat panel X-ray detectors and infectious disease testing for the diagnostics market. This segment also develops technologies that enable and support sample-to-sequencer workflow using next-generation DNA sequencing for applications in oncology, genetic testing, and drug discovery. The company serves pharmaceutical and biotechnology companies, laboratories, academic and research institutions, public health authorities, private healthcare organizations, doctors, and government agencies. PerkinElmer, Inc. was founded in 1931 and is headquartered in Waltham, Massachusetts.